EISMEA
VC Fund
Brussels, Belgium
EISMEA is a VC fund in Brussels focused on Biotechnology and Software. EASME is a European Union executive agency that supports small and medium-sized enterprises and promotes innovation in Europe. It manages projects in the areas of small and medium-sized enterprises, as well as the environment, energy, and maritime sectors, funded by COSME, LIFE, and EMFF. EASME organizes the European Sustainable Energy Week andserves industries such as environmental management, energy production, and maritime activities.
- Total investments:
- 176
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries EISMEA invests in
Stages EISMEA invests in
Countries EISMEA invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Seed
- $54k–$2.3M
- Grant
- $57k–$2.8M
- Venture - Series Unknown
- $1.4M–$9M
Investment Focus
Industry
- Biotechnology 42 (24%)
- Software 35 (20%)
- Health Care 35 (20%)
- Medical Device 26 (15%)
- Information Technology 24 (14%)
Stage
- Grant 166 (94%)
- Seed 5 (3%)
- Venture - Series Unknown 3 (2%)
- Debt Financing 1 (1%)
Country
- Spain 29 (16%)
- Switzerland 16 (9%)
- United Kingdom 16 (9%)
- The Netherlands 14 (8%)
- Germany 13 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Vesa Terava
Head of Unit Regulatory Coordination & Users, DG Connect
|
Head of Unit Regulatory Coordination & Users, DG Connect | Total investments: 0 | Find email | |
Gary Cige
Consultant, Startup Europe HQ
|
Consultant, Startup Europe HQ | Total investments: 0 | Find email | |
Hugo Monteiro Brilhante Sobral
Deputy Head of Cabinet, Diplomatic Adviser
|
Deputy Head of Cabinet, Diplomatic Adviser | Total investments: 0 | Find email | |
Mark Van Stiphout
Deputy Head of Unit - Research and Innovation , DG Energy
|
Deputy Head of Unit - Research and Innovation , DG Energy | Total investments: 0 | Find email | |
|
Philipp Gasparon
Acting Head of Unit, Pharma Antitrust Unit, DG Competition
|
Acting Head of Unit, Pharma Antitrust Unit, DG Competition | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AGADE specialising in robotic exoskeletons. The company created its first product, AGADEXO, which can significantly reduce muscle fatigue and the risk of injury associated with repetitive and dynamic activities. They provide variable support, eliminating the effect of gravity on human limbs and allowing movements comparable to those possible in azero-g environment. | $9M / Venture - Series Unknown / Apr 14, 2022 | ||
| BroadBit Batteries is developing revolutionary new batteries using novel sodium-based chemistries to power the future green economy. They are developing revolutionary new batteries using novel sodium-based chemistries to power the future green economy.They have already made high-performance lab samples and are now commercializing the technologyfor next-generation electric vehicles, portable electronics, starters, and grid energy storage. | $2.8M / Grant / Dec 20, 2021 | ||
| Created in July 2014, Aenitis Technologies is a French start-up resulting from the work of Mauricio HOYOS and Jean-Luc AIDER, both CNRS researchers at the PMMH Laboratory (Physics and Mechanics of Heterogeneous Media at the ESPCI ParisTech, a research engineer’s school in Paris. The company focuses on medical devices’ area, where their breakthroughtechnologies are highly promising. Aenitis Technologies is developing innovative separation, manipulation and filtration of biological elements solutions, based on acoustophoresis technologies. The company first focuses on technological solutions that will revolutionize current practices in Public Health. Aenitis Technologies aims to become a world leader in filtering / separating solutions by acoustophoresis. | Grant / Jun 16, 2021 | ||
| Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and will shortly enter clinical trials. FibroFix™ technology will then be rolled out to treat other joints and Orthox also has pipeline developments beyond orthopaedics in which strength and tissue regeneration are key. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™. | $2.8M / Grant / Jul 01, 2020 | ||
| Vital Beats combines participatory design and data science with nordic aesthetics to ensure that it’s both enjoyable and valuable to use their platform. Their platform never sleeps and constantly triages every cardiac device patient using their patent-pending technique. | $2.3M / Seed / Jul 01, 2020 | ||
| Brevel developed a disruptive cultivation technology for sustainable, low cost and high quality production of microalgae for various yet untapped markets. The technology is based on high-tech indoor, sterile and fully automated systems which are illuminated from within at high intensity. The technology enables the surprising results of more than90% cost reduction and up to 200 higher yields compared to current alternatives. Brevel is using the advantageous production capabilities to enter multiple markets where microalgae derived products are needed. | $1.3M / Grant / Apr 01, 2020 | ||
| QDevil aim of enhancing the science in quantum electronics labs, by enabling scientists to focus their effort on the science, instead of constructing auxiliary equipment that already has been developed in other labs.The products of QDevil have been used and thoroughly tested in some of the world’s leading quantum electronics labs. The initialproduct of QDevil is the QFilter, which has been developed and tested at Harvard University and University of Copenhagen for over five years. | $1.1M / Grant / Mar 01, 2020 | ||
| Didimo is the world’s leading provider of fast, automated solutions for the generation of high-quality real-time humans. Our high-fidelity 3D didimo human avatars are created in around 90 seconds, from inputs as simple as a 2D photo.Our PaaS allows content creators, software developers, collaboration platforms, and app builders to integrate afast, robust, and reliable solution for generating user-generated avatars in their own software solutions. Our patented and flexible pipeline can translate various image-based inputs of a user’s face, and using automated machine vision, topology generation, texturing, and rigging components, to output a real-time ready high fidelity avatar. These are designed to be perfectly suited for real-time engines - and include a full facial animation system and text-to-speech animation capability. | $2M / Grant / Dec 17, 2019 | ||
| NORAKER specializes in the design, production, and marketing of synthetic and bioactive biomaterial-based implantable medical devices for bone substitution and osteosynthesis.The company has been able to establish a close and regular collaboration with health professionals to meet a demanding market, with one goal: to improve the comfort ofpatients. Noraker has built its development on a strategy of differentiation through innovation, using bioactive glass, active ceramic second generation, in the design of its medical devices. | $2.8M / Grant / Dec 01, 2019 | ||
| Trovant Technology specializes in the development of bio-based technologies for organic waste treatment and valorization, transforming this waste into bioenergy. They develop proprietary technology and tailor-made solutions, always keeping the market in mind. At the moment they are focusing on biogas upgrading and biomethane with UBI - BiologicalIntegral Biogas Upgrading. | $55.4K / Grant / Oct 26, 2019 | ||
| See all 176 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does EISMEA invest in?
EISMEA invests primarily in Biotechnology, Software and Health Care startups, most often at Grant and Seed stage. Most of the 176 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is EISMEA's check size?
EISMEA typically joins rounds of $54k–$2.3M at Seed, $57k–$2.8M at Grant and $1.4M–$9M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds EISMEA participates in.
How do I contact EISMEA?
Public channels for EISMEA include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EISMEA?
The team at EISMEA includes Vesa Terava (Head of Unit Regulatory Coordination & Users, DG Connect), Gary Cige (Consultant, Startup Europe HQ) and Hugo Monteiro Brilhante Sobral (Deputy Head of Cabinet, Diplomatic Adviser), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
